Cost-Utility Analysis of Once-Weekly Semaglutide, Dulaglutide, and Exenatide for Type 2 Diabetes Patients Receiving Metformin-Based Background Therapy in China

• Główni autorzy: Shanshan Hu (Autor), Shuowen Wang (Autor), Chendong Qi (Autor), Shengying Gu (Autor), Chenyang Shi (Autor), Lin Mao (Autor), Guorong Fan (Autor)
• Format: Książka
• Wydane: Frontiers Media S.A., 2022-02-01T00:00:00Z.
• Hasła przedmiotowe: article
• Dostęp online: Connect to this object online.

Introduction: The substantial financial burden associated with type 2 diabetes (T2D) over a lifetime cannot be neglected. Therefore, the objective of this study was to evaluate the pharmacoeconomic value of three once-weekly GLP-1 RAs, namely subcutaneous semaglutide (sc. SEMA), dulaglutide (DULA),...